Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adipose-derived mesenchymal stem cell secretome
- Development stage
- Unknown
- Lead developer
- Dr. Cipto Mangunkusumo Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Adipose-derived mesenchymal stem cell secretome is a cell-free therapeutic agent consisting of the complete set of paracrine factors—including cytokines, chemokines, growth factors, and extracellular vesicles—secreted by mesenchymal stem cells (MSCs) derived from adipose tissue. Developed by Indonesia University (Universitas Indonesia), it is being investigated for the treatment of Multiple System Atrophy (MSA). The secretome is intended to stop clinical neurodegeneration by providing local support for damaged tissue and promoting regeneration through the delivery of neurotrophic factors such as IGF-1 and BDNF. In clinical trial settings, it has been administered intravenously as part of a regimen that may also include the intrathecal implantation of umbilical cord-derived MSCs.
- Other names
- Adipose MSC secretomeMSC-Adipose secretomeAdipose secretomeAdipose-derived MSC secretome
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)MET (Mesenchymal-epithelial transition factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR (TGF-beta receptor)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR (VEGFR family)BDNF (Brain-derived neurotrophic factor)IGF-1 (Insulin-like growth factor 1)
Beyond the preview
Go deeper on adipose-derived mesenchymal stem cell secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adipose-derived mesenchymal stem cell secretome.